Skip to main content

Table 3 sLep, sLepR and respective fat mass ratios of RA patients according to BMI and anti-CCP status

From: Serum leptin and serum leptin/serum leptin receptor ratio imbalance in obese rheumatoid arthritis patients positive for anti-cyclic citrullinated peptide antibodies

  Normal weight   Preobese   Obese  
BMI 18.50–24.99 kg/m2 BMI 25.00–29.99 kg/m2 BMI ≥30.00 kg/m2
Anti-CCP
Measurement Negative Positive P Negative Positive P Negative Positive P
n = 6 n = 15 n = 8 n = 13 n = 4 n = 18
sLep, ng/Ml 51.09 ± 29.76 43.93 ± 44.54 0.267 66.90 ± 51.78 155.34 ± 118.56 0.104 104.04 ± 29.21 206.91 ± 101.91 0.033
sLepR, ng/Ml 60.46 ± 14.20 59.82 ± 21.13 0.898 56.47 ± 13.79 48.49 ± 11.55 0.518 45.89 ± 4.63 35.39 ± 9.55 0.101
sLep/sLepR, ng/Ml 0.89 ± .49 1.02 ± 1.69 0.244 1.36 ± 1.43 3.05 ± 2.75 0.240 2.13 ± 0.86 6.55 ± 3.43 0.048
sLep/fat mass, ng/mL/kg 3.44 ± 1.72 2.86 ± 2.08 0.564 2.73 ± 2.30 6.39 ± 4.98 0.053 3.27 ± 0.87 5.77 ± 2.73 0.033
sLepR/fat mass, ng/mL/kg 4.11 ± 1.01 4.78 ± 2.79 0.925 2.25 ± 0.65 1.99 ± 0.43 0.529 1.45 ± 0.27 1.01 ± 0.39 0.101
  1. Continuous variables are represented as mean ± standard deviation; the Mann-Whitney U test was used to compare differences between groups. BMI body bas index, anti-CCP anti-cyclic citrullinated peptide antibodies, sLep serum leptin, sLepR soluble leptin receptor)